Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.

Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.

Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.

Non-small Cell Lung Cancer (NSCLC)

Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.

Ginsenoside H dripping pills

Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.

Ginsenoside H dripping pills+Placebo

Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.

Placebo

Guangdong Provincial Hospital of TCM

The First Affiliated Hospital of Guangzhou University of TCM

Jiangsu Provincial Hospital of Integrated Chinese Traditional and Western Medicine

Jing'an District Centre Hospital of Shanghai

Shuguang Hospital Affiliated with Shanghai University of TCM

West China Hospital ,Sichuan University

The Second People's Hospital of Yibin

Tianjin People's Hospital

Hangzhou First People's Hospital

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)

Evaluate progression free survival (PFS) in the 3 groups : 0 , every 8 weeks and the end of treatment

Evaluate overall survival (OS) in the 3 groups

Evaluate time to progression(TTP) in the 3 groups

[0 , every 4 weeks and the end of treatment] To determine the quality of life by using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scales.

0 , every 4 weeks and the end of treatment

Evaluate the fatigue degree in the 3 groups using the Chinese version of Brief Fatigue Index (BFI-C): 0 , every 4 weeks and the end of treatment

0 , every 4 weeks during the period of 0 to 16 weeks, every 8 weeks after 16 weeks and the end of treatment

Tasly Pharmaceuticals, Inc.

Ginsenoside Rg3 plus First-line Chemotherapy

Self Efficacy

Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression
XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression

XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression

First-line Chemotherapy

Hebei Tumor Hospital

Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence

160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group

Stage I Hepatocellular Carcinoma

Stage II Hepatocellular Carcinoma

the ginsenoside Rg3

The First Affiliated Hospital of Fujian Medical University

Tumor Hospital,Sun Yat-san University

The First Affiliated Hospital of Harbin Medical University

Tongji Hospital,Huazhong University of Science ＆ Technology

Zhongshan hospital,Fudan University

the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

the interval between the initial hepatectomy and date of diagnosis of recurrent HCC

the interval between the date of the initial hepatectomy and the date of death or last follow-up

the adverse reactions of the application of ginsenoside Rg3,for example:severe dry pharynx

ShenFeng

vice president of the Eastern Hepatobiliary Surgery Hospital

Huazhong University of Science and Technology

Shanghai Zhongshan Hospital

Sun Yat-sen University

First Affiliated Hospital of Harbin Medical University

First Affiliated Hospital of Fujian Medical University

four, 250mg tablets daily 5-14 days prior to surgery

Breast Cancer

American Ginseng root

Simmons Cancer Institute-SIU School of Medicine

A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer

Change from baseline following 10-14 days of treatment with LEAG.

Mean change from baseline following 10-14 days of treatment with LEAG.

Southern Illinois University

Erosive Gastritis

PDC339

Department of Internal Medicine, National Taiwan University Hospital

A Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis

A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparative Phase II Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis

ginsenoside f 1/kansè

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer

A Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis

Baz done ki pi konplè remèd fèy medsin te apiye nan syans